Commonalities and Differences in Myeloid Malignancies: Insights from the EHA-SWG Scientific Meeting on MDS, MPN, and AML
November 2-4 - Budapest, Hungary
Meeting Chairs:
- Konstanze Döhner, University Hospital Ulm, Germany
- Claire Harrison, Guy's and St. Thomas' Hospital, London, United Kingdom
- Uwe Platzbecker, Leipzig University Hospital, Leipzig, Germany
Co-chairs:
- Jean-Jacques Kiladjian, Saint-Louis Hospital & Paris Diderot University, Paris, France
- Shahram Kordasti, King’s College London, London, United Kingdom
- Gert Ossenkoppele, Amsterdam UMC, Amsterdam, the Netherlands
EHA and the Specialized Working Groups (SWG) on Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), and Acute Myeloid Leukemia (AML) hosted the first of its kind: a scientific meeting exploring commonalities and overlaps in myeloid malignancies, and important differences in current understandings of the pathophysiology, novel treatments and future of therapy in these diverse areas.
The following list of topics were covered:
- Commonalities and Differences of MDS, MPN and AML
- Genomics in MPN, MDS, AML
- HSC Niche
- Immunome in MPN, MDS and AML
- Development of biomarkers of disease progression
- Translating Omics to Clinical Tests
- Novel therapies
- HSC transplant and cell therapy
More than 30 presentations over the course of 3 days in November 2023 allowed chairs U Platzbecker, K Döhner, C Harrison, and a wide range of experts to debate and share insights across a broad range of topics.
The meeting also included panel discussions, meet-the-expert sessions, oral abstract sessions, and a poster session. This range of sessions allowed for both wider debates on fundamental tools such as the microscope and flow cytometer, management of disease entities, and in individual details in clinical case discussions.
Meeting attendees following a session.
Highlights included opportunities to learn about different approaches to rare overlapping entities such as chronic myelomonocytic leukemia and the nuances of differences between WHO and ICC diagnostic criteria that were published in 2022 and how we are all using these in practice. In addition, fascinating insights into clonal hemopoiesis, and clonal evolution have been presented nicely reflecting the continuum of the diseases.
The meeting had a hybrid format, providing attendees, both in-person and online, with the opportunity for Q&A and enabling lively discussions, not least on different approaches to rare overlapping entities, insights into the stem cell niche in aging, and the debate on cytometry versus morphology.
Attendees discussing at a roundtable session.
It has been quite the best meeting of the year I have attended, I really enjoyed it, and it was mostly relevant to my patients – Anonymous attendee
By the end of the meeting, participants were able to:
- Have an up-to-date understanding of the pathogenesis and diagnosis of MDS, MPN, and AML
- Appreciate state-of-the-art developments in treatment as well as in the context and views in areas of uncertainty
- Be fluent in current research and the translation to treatment
- Have had the opportunity to dialogue with and between experts in the field
After the conference, I deeply feel the dedication of domestic hematology societies in organizing courses. – Anonymous attendee
Faculty and participants expressed that the meeting was stimulating and successfully met its objective, and a desire to organize a follow-up meeting in the coming years was widely shared.
The program was very well structured, with a mixture of educational and cut-edge sessions. – Faculty member
Back